Business · 25/08/2025
FDA Announces Public Meeting on Prescription Drug User Fee Act and Biosimilar User Fee Amendments Hiring and Retention Assessment
The US Food and Drug Administration (FDA) is hosting a public meeting to discuss the results of a hiring and retention assessment related to the Prescription Drug User Fee Act and Biosimilar User Fee Amendments.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →